#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thalassaemia alpha Central nervous system neoplasm Small intestine leiomyosarcoma KBG syndrome Primary myelofibrosis Hereditary optic atrophy Macular telangiectasia Astrocytoma malignant Scedosporium infection Progressive familial intrahepatic cholestasis Ductal adenocarcinoma of pancreas Giant cell tumour of tendon sheath Neonatal alloimmune thrombocytopenia Thalassaemia Kidney transplant rejection More trials…

    Learn about Rare Diseases

    Mastocytosis – Basic Information Langerhans cell sarcoma – Basic Information Haemophagocytic lymphohistiocytosis – Basic Information Rhabdomyosarcoma recurrent – Treatment CADASIL – Treatment Netherton’s syndrome – Treatment Gastrointestinal stromal tumour – Trials in Disease Brain stem glioma – Treatment Krabbe’s disease Phenylketonuria – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    GSK5458514 ALN-4324 Sapropterin Dihydrochloride H2-Receptor Antagonist Cortisone Acetate Sodium S-Lactate Solution ZINC CHLORIDE Clazakizumab Valine GSKVX000000070965 Pyridoxine Hydrochloride Bp Human Coagulation Factor Ix Clobetasol Selgantolimod Rondaptivon Pegol Magnesium Hydroxide Nanatinostat Dalbavancin COBALAMIN Nadroparin Calcium More therapies…

    Learn about Your Condition

    Myotonic dystrophy HER2 positive breast cancer COVID-19 Malignant melanoma stage III Chondrocalcinosis Invasive breast carcinoma Congenital pseudarthrosis Lennox-Gastaut syndrome Mantle cell lymphoma stage II Lung adenocarcinoma stage IV Delayed graft function Acute leukaemia Pancreatitis relapsing Follicular lymphoma Advanced systemic mastocytosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Thalassaemia beta

  • A Study of Gene Therapy Using Modified Stem Cells for Patients with Transfusion-Dependent Beta-Thalassemia Who Need Regular Blood Transfusions

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Thalassaemia beta
    • Thalassaemia
    Investigated Drugs:
    • Lenograstim
    • Autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene
    • Plerixafor
    Italy

  • Study on the Effects of Exagamglogene Autotemcel for Patients with Transfusion-Dependent Beta-Thalassemia or Severe Sickle Cell Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Sickle cell anaemia
    • Thalassaemia beta
    Investigated Drugs:
    • Exagamglogene Autotemcel
    • Plerixafor
    • Filgrastim
    Germany Italy

  • Study on Luspatercept for Improving Brain Oxygenation in Patients with Non-Transfusion Dependent Thalassemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Thalassaemia beta
    • Thalassaemia
    Investigated Drugs:
    • Luspatercept
    The Netherlands

  • Study on the Safety and Effects of Luspatercept for Children with Beta Thalassemia

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Thalassaemia beta
    Investigated Drugs:
    • Luspatercept
    Germany Greece Italy

  • Study of SP-420 for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

    Recruiting

    2 1 1
    Investigated Drugs:
    • (S)-4,5-Dihydro-2-[2-Hydroxy-4-(3,6-Dioxaheptyloxy)Phenyl]-4-Methyl-4-Thiazolecarboxylic Acid
    Denmark Greece Italy Poland

  • Evaluation of the Efficacy, Safety, and Tolerability of Subcutaneous REGN7999 in Adults with Iron Overload Due to Non-Transfusion Dependent Beta-Thalassemia

    Not recruiting

    2 1
    Investigated Drugs:
    • REGN7999
    Greece Italy
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!